WHO ICTRP trial
A Phase II trial to assess the efficacy and safety of pasireotide s.c. alone or…
NL-OMON42150 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON42150 |
|---|---|
| Public title | A Phase II trial to assess the efficacy and safety of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing*s disease |
| Scientific title | A Phase II trial to assess the efficacy and safety of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing*s disease - CSOM230B2411 |
| Primary sponsor | Novartis |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands ;Spain;Turkey;United Kingdom;United States of America ;Venezuela |
| Conditions | Cushing's disease;10021112;Cushing's disease |
| Interventions | Treatment with pasireotide alone or in combination with cabergoline. ;cabergoline;Cushing's disease;pasireotide;somatostatin analogue |
| Registration date | Dec 17, 2015 |
| Target size | 2 |
| Secondary IDs | 2013-002170-49;NCT01915303;NL49601.078.14 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: